drugset / Trial / NCT06694480
Study of FID-022 in Participants With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.
Timeline
- Start
- 2025-07-03
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FID-022 | Unknown | 20 mg/m2 | Intravenous |
| Subject | FID-022 | Unknown | 40 mg/m2 | Intravenous |
| Subject | FID-022 | Unknown | 60 mg/m2 | Intravenous |
| Subject | FID-022 | Unknown | 80 mg/m2 | Intravenous |
| Subject | FID-022 | Unknown | 100 mg/m2 | Intravenous |
| Subject | FID-022 | Unknown | 120 mg/m2 | Intravenous |